Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
Bi Z, Jiao Z, Li J, Fang Z
Summary
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and depression risk across multiple studies. The analysis examined psychiatric safety signals in patients treated with semaglutide, liraglutide, and other GLP-1 RAs, addressing the ongoing FDA-mandated scrutiny of mental health outcomes with incretin-based therapies.
Clinical Significance
Critical safety data for prescribers managing the growing population on GLP-1 RAs for obesity and diabetes. With over 12% of US adults having used GLP-1 drugs, understanding psychiatric risk profiles is essential for informed clinical decision-making and patient counseling.
Pesquisa Relacionada
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…
GLP-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control
This review synthesizes preclinical and clinical evidence showing that GLP-1 RAs may reduce platelet…
GLP-1 Analogs Activate AMP Kinase Leading to Reversal of the Warburg Effect in Breast Cancer Cells
GLP-1 receptor agonists were shown to activate AMP kinase and reverse the Warburg metabolic switch i…